Company / Return on Equity (ROE)
Coherus Oncology, Inc. Return on Equity (ROE) History
FY2014-FY2019 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
85.4%
FY2019
5-year range
-780.0% / 85.4%
FY2015-FY2019
Trend
-
vs FY2018
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Return on Equity (ROE) returned to growth in FY2019 after 2 years of decline, reaching 85.4%.
Based on SEC 10-K filings.
85.4% in FY2019 with a 5-year CAGR of +134.8%.
Improved from -424.5% to 85.4% over the past 3 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- +509.9pp
- 5-Year Change
- +134.8pp
- 10-Year Change
- -
Company context
Key Data Points
- Altman Z-Score -0.49 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2019 | 85.4% | - |
| FY2018 | - | - |
| FY2017 | -780.0% | -83.8% |
| FY2016 | -424.5% | - |
| FY2015 | - | - |
| FY2014 | -49.4% | - |
As of FY2019 · SEC 10-K · Updated Jun 24, 2026